Aquaglyceroporins and metalloid transport: Implications in human diseases

Handbook of Experimental Pharmacology

Volumn 190, Issue , 2009, Pages 309-325

  Mukhopadhyay, Rita ^a   Bhattacharjee, Hiranmoy ^b   Rosen, Barry P ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; AQUAGLYCEROPORIN; AQUAPORIN 1; AQUAPORIN 3; AQUAPORIN 4; AQUAPORIN 7; AQUAPORIN 9; ARSENIC; ARSENIC TRIOXIDE; GLYCEROL; MEGLUMINE ANTIMONATE; MELARSOPROL; PENTAMIDINE; RETINOIC ACID; STIBOGLUCONATE SODIUM; SURAMIN; WATER; ANTINEOPLASTIC AGENT; ANTIPROTOZOAL AGENT; ORGANOARSENIC DERIVATIVE;

ADJUVANT THERAPY; AFRICAN TRYPANOSOMIASIS; ANTIPROTOZOAL ACTIVITY; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CYTOTOXICITY; DETOXIFICATION; DIFFUSION; DRUG MECHANISM; ESCHERICHIA COLI; HOMEOSTASIS; HUMAN; INTRACELLULAR TRANSPORT; ION CONDUCTANCE; LEISHMANIA; MEMBRANE PERMEABILITY; MOLECULAR MIMICRY; NONHUMAN; OSMOREGULATION; PH; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SACCHAROMYCES CEREVISIAE; SOLUTE; VISCERAL LEISHMANIASIS; XENOPUS LAEVIS; ANIMAL; EUKARYOTIC CELL; METABOLISM; PROKARYOTIC CELL; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTIMONY; ANTINEOPLASTIC AGENTS; ANTIPROTOZOAL AGENTS; AQUAGLYCEROPORINS; ARSENICALS; BIOLOGICAL TRANSPORT; EUKARYOTIC CELLS; HUMANS; PROKARYOTIC CELLS;

EID: 61449375176     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-79885-9_16     Document Type: Review

References (82)

1. Abedin MJ, Cresser MS, Meharg AA, Feldmann J, Cotter-Howells J (2002) Arsenic accumulation and metabolism in rice (Oryza sativa L.). Environ Sci Technol 36:962-968.
2. Abernathy CO, Thomas DJ, Calderon RL (2003) Health effects and risk assessment of arsenic. J Nutr 133:1536S-1538S.
3. Agre P, Kozono D (2003) Aquaporin water channels: molecular mechanisms for human diseases. FEBS Lett 555:72-78
4. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G, Cortes JE (2007) Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 109:1355-1359
5. Arima H, Yamamoto N, Sobue K, Umenishi F, Tada T, Katsuya H, Asai K (2003) Hyperosmolar mannitol simulates expression of aquaporins 4 and 9 through a p38 mitogen-activated protein kinase-dependent pathway in rat astrocytes. J Biol Chem 278:44525-44534
6. Aronson SM (1994) Arsenic and old myths. R I Med 77:233-234
7. Beitz E (2005) Aquaporins from pathogenic protozoan parasites: structure, function and potential for chemotherapy. Biol Cell 97:373-383
8. Bhattacharjee H, Rosen BP (2007) Arsenic metabolism in prokaryotic and eukaryotic microbes. In: Nies DH, Silver S (eds.) Molecular microbiology of heavy metals. Springer, Berlin/Heidelberg, pp. 371-406
9. Bhattacharjee H, Carbrey J, Rosen BP, Mukhopadhyay R (2004) Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9. Biochem Biophys Res Commun 322: 836-841
10. Bobrowicz P,Wysocki R, Owsianik G, Goffeau A, Ulaszewski S (1997) Isolation of three contiguous genes, ACR1, ACR2 and ACR3, involved in resistance to arsenic compounds in the yeast Saccharomyces cerevisiae. Yeast 13:819-828
11. Bouteille B, Oukem O, Bisser S, Dumas M (2003) Treatment perspectives for human African trypanosomiasis. Fundam Clin Pharmacol 17:171-181
12. Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, Atwater S, Bishop JM (1997) A PMLRARα transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A 94:2551-2556
13. Bun-ya M, Shikata K, Nakade S, Yompakdee C, Harashima S, Oshima Y (1996) Two new genes, PHO86and PHO87, involved in inorganic phosphate uptake in Saccharomyces cerevisiae. Curr Genet 29:344-351
14. Butler TL, Au CG, Yang B, Egan JR, Tan YM, Hardeman EC, North KN, Verkman AS, Winlaw DS (2006) Cardiac aquaporin expression in humans, rats, and mice. Am J Physiol Heart Circ Physiol 291:H705-H713
15. Caperna TJ, Shannon AE, Richards MP, Garrett WM, Talbot NC (2007) Identification and characterization of aquaporin-9 (AQP9) in porcine hepatic tissue and hepatocytes in monolayer culture. Domest Anim Endocrinol 32:273-286
16. Carbrey JM, Gorelick-Feldman DA, Kozono D, Praetorius J, Nielsen S, Agre P (2003) Aquaglyceroporin AQP9: solute permeation and metabolic control of expression in liver. Proc Natl Acad Sci U S A 100:2945-2950
17. Choi CM, Lerner EA (2002) Leishmaniasis: recognition and management with a focus on the immunocompromised patient. Am J Clin Dermatol 3:91-105
18. Cioli D, Pica-Mattoccia L, Archer S (1995) Antischistosomal drugs: past, present. . . and future?. Pharmacol Ther 68:35-85
19. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902-5910
20. de Koning HP (2001) Transporters in African trypanosomes: role in drug action and resistance. Int J Parasitol 31:512-522
21. Decuypere S, Rijal S, Yardley V, De Doncker S, Laurent T, Khanal B, Chappuis F, Dujardin JC (2005) Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal. Antimicrob Agents Chemother 49:4616-4621
22. Denton H, McGregor JC, Coombs GH (2004) Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. Biochem J 381:405-412
23. Dilda PJ, Hogg PJ (2007) Arsenical-based cancer drugs. Cancer Treat Rev 33:542-564
24. Faraut-Gambarelli F, Piarroux R, Deniau M, Giusiano B, Marty P, Michel G, Faugere B, Dumon H (1997) In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother 41:827-830
25. Figarella K, Uzcategui NL, Zhou Y, Lefurgey A, Ouellette M, Bhattacharjee H, Mukhopadhyay R (2007) Biochemical characterization of Leishmania major aquaglyceroporin LmAQP1: possible role in volume regulation and osmotaxis. Mol Microbiol 65:1006-1017
26. Fu D, Libson A, Miercke LJ, Weitzman C, Nollert P, Krucinski J, Stroud RM (2000) Structure of a glycerol-conducting channel and the basis for its selectivity. Science 290:481-486
27. Ghosh M, Shen J, Rosen BP (1999) Pathways of As(III) detoxification in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 96:5001-5006
28. Goodwin LG (1995) Pentostam (sodium stibogluconate); a 50-year personal reminiscence. Trans R Soc Trop Med Hyg 89:339-341
29. Gourbal B, Sonuc N, Bhattacharjee H, Legare D, Sundar S, Ouellette M, Rosen BP, Mukhopadhyay R (2004) Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem 279:31010-31017
30. Hannaert V, Saavedra E, Duffieux F, Szikora JP, Rigden DJ, Michels PA, Opperdoes FR (2003) Plant-like traits associated with metabolism of Trypanosoma parasites. Proc Natl Acad Sci U S A 100:1067-1071
31. Hara-Chikuma M, Verkman AS (2006) Physiological roles of glycerol-transporting aquaporins: the aquaglyceroporins. Cell Mol Life Sci 63:1386-1392
32. Healy SM, Casarez EA, Ayala-Fierro F, Aposhian H (1998) Enzymatic methylation of arsenic compounds. V. Arsenite methyltransferase activity in tissues of mice. Toxicol Appl Pharmacol 148:65-70
33. Hughes MF, Kenyon EM, Edwards BC, Mitchell CT, Razo LM, Thomas DJ (2003) Accumulation and metabolism of arsenic in mice after repeated oral administration of arsenate. Toxicol Appl Pharmacol 191:202-210
34. Jackson JE, Tally JD, Ellis WY, Mebrahtu YB, Lawyer PG, Were JB, Reed SG, Panisko DM, Limmer BL (1990) Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania ssp. from patients unresponsive to pentavalent antimony therapy. Am J Trop Med Hyg 43:464-480
35. Kala SV, Neely MW, Kala G, Prater CI, Atwood DW, Rice JS, Lieberman MW (2000) The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem 275:33404-33408
36. Kenyon EM, Del Razo LM, Hughes MF (2005) Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in mice following acute oral administration of arsenate. Toxicol Sci 85:468-475
37. King LS, Kozono D, Agre P (2004) From structure to disease: the evolving tale of aquaporin biology. Nat Rev Mol Cell Biol 5:687-698
38. Klaassen CD (1996) Heavy metals and heavy metal antagonists. McGraw-Hill, New York
39. Kwong YL, Todd D (1997) Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 89:3487-3488
40. Lee TC, Ho IC, Lu WJ, Huang JD (2006) Enhanced expression of multidrug resistance-associated protein 2 and reduced expression of aquaglyceroporin 3 in an arsenic-resistant human cell line. J Biol Chem 281:18401-18407
41. Leung J, Pang A, Yuen WH, Kwong YL, Tse EW (2007) Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood 109:740-746
42. Liu J, Chen H,Miller DS, Saavedra JE, Keefer LK, Johnson DR, Klaassen CD,WaalkesMP (2001) Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol 60:302-309
43. Liu Z, Shen J, Carbrey JM, Mukhopadhyay R, Agre P, Rosen BP (2002) Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc Natl Acad Sci U S A 99:6053-6058
44. Liu Z, Carbrey JM, Agre P, Rosen BP (2004) Arsenic trioxide uptake by human and rat aquaglyceroporins. Biochem Biophys Res Commun 316:1178-1185
45. Liu Z, Styblo M, Rosen BP (2006) Methylarsonous acid transport by aquaglyceroporins. Environ Health Perspect 114:527-531
46. Marquis N, Gourbal B, Rosen BP, Mukhopadhyay R, Ouellette M (2005) Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol Microbiol 57:1690- 1699
47. Meng YL, Liu Z, Rosen BP (2004) As(III) and Sb(III) uptake by GlpF and efflux by ArsB in Escherichia coli. J Biol Chem 279:18334-18341
48. Mottram JC, Coombs GH (1985) Leishmania mexicana: enzyme activities of amastigotes and promastigotes and their inhibition by antimonials and arsenicals. Exp Parasitol 59:151-160
49. Mukhopadhyay R, Shi J, Rosen BP (2000) Purification and characterization of Acr2p, the Saccharomyces cerevisiae arsenate reductase. J Biol Chem 275:21149-21157
50. Muramatsu S, Mizuno T (1989) Nucleotide sequence of the region encompassing the glpKF operon and its upstream region containing a bent DNA sequence of Escherichia coli. Nucleic Acids Res 17:4378
51. Pastor-Soler N, Isnard-Bagnis C, Herak-Kramberger C, Sabolic I, Van Hoek A, Brown D, Breton S (2002) Expression of aquaporin 9 in the adult rat epididymal epithelium is modulated by androgens. Biol Reprod 66:1716-1722
52. Porquet A, Filella M (2007) Structural evidence of the similarity of Sb(OH)3 and As(OH)3 with glycerol: implications for their uptake. Chem Res Toxicol 20:1269-1276
53. Ramirez-Solis A, Mukopadhyay R, Rosen BP, Stemmler TL (2004) Experimental and theoretical characterization of arsenite in water: insights into the coordination environment of As-O. Inorg Chem 43:2954-2959
54. Richey DP, Lin EC (1972) Importance of facilitated diffusion for effective utilization of glycerol by Escherichia coli. J Bacteriol 112:784-790
55. RobertsWL, Berman JD, Rainey PM(1995) In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob Agents Chemother 39:1234-1239
56. Rosenberg H, Gerdes RG, Chegwidden K (1977) Two systems for the uptake of phosphate in Escherichia coli. J Bacteriol 131:505-511
57. Sanders OI, Rensing C, Kuroda M, Mitra B, Rosen BP (1997) Antimonite is accumulated by the glycerol facilitator GlpF in Escherichia coli. J Bacteriol 179:3365-3367
58. Sanno Y,Wilson TH, Lin EC (1968) Control of permeation to glycerol in cells of Escherichia coli. Biochem Biophys Res Commun 32:344-349
59. Sereno D, Lemesre JL (1997) Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother 41:972-976
60. Sereno D, Cavaleyra M, Zemzoumi K, Maquaire S, Ouaissi A, Lemesre JL (1998) Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob Agents Chemother 42:3097-3102
61. Silva ES, Pacheco RS, Gontijo CM, Carvalho IR, Brazil RP (2002) Visceral leishmaniasis caused by Leishmania (Viannia) braziliensis in a patient infected with human immunodeficiency virus. Rev Inst Med Trop Sao Paulo 44:145-149
62. Sundar S, More DK, Singh MK, Singh VP, Sharma S,Makharia A, Kumar PC, Murray HW(2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31:1104-1107
63. Sweet G, Gandor C, Voegele R, Wittekindt N, Beuerle J, Truniger V, Lin EC, Boos W (1990) Glycerol facilitator of Escherichia coli: cloning of glpF and identification of the glpF product.
64. J Bacteriol 172:424-430
65. Thomas DJ,Waters SB, Styblo M (2004) Elucidating the pathway for arsenic methylation. Toxicol
66. Appl Pharmacol 198:319-326
67. Thorsen M, Di Y, Tangemo C, Morillas M, Ahmadpour D, Van der Does C, Wagner A, Johansson E, Boman J, Posas F, Wysocki R, Tamas MJ (2006) The MAPK Hog1p modulates Fps1p-dependent arsenite uptake and tolerance in yeast. Mol Biol Cell 17:4400-4410
68. Uzcategui NL, Szallies A, Pavlovic-Djuranovic S, Palmada M, Figarella K, Boehmer C, Lang F, Beitz E, Duszenko M (2004) Cloning, heterologous expression, and characterization of three aquaglyceroporins from Trypanosoma brucei. J Biol Chem 279:42669-42676
69. Verma A, Mohindru M, Deb DK, Sassano A, Kambhampati S, Ravandi F, Minucci S, Kalvakolanu DV, Platanias LC (2002) Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem 277:44988-44995
70. Verstovsek S, Giles F, Quintas-Cardama A, Perez N, Ravandi-Kashani F, Beran M, Freireich E, Kantarjian H (2006) Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? Hematol Oncol 24:181-188
71. Wang CC (1995) Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol 35:93-127
72. Wang CH, Hsiao CK, Chen CL, Hsu LI, Chiou HY, Chen SY, Hsueh YM, Wu MM, Chen CJ (2007) A review of the epidemiologic literature on the role of environmental arsenic exposure and cardiovascular diseases. Toxicol Appl Pharmacol 222:315-326
73. Willsky GR, Malamy MH (1980a) Characterization of two genetically separable inorganic phosphate transport systems in Escherichia coli. J Bacteriol 144:356-365
74. Willsky GR, Malamy MH (1980b) Effect of arsenate on inorganic phosphate transport in Escherichia coli. J Bacteriol 144:366-374
75. Wysocki R, Bobrowicz P, Ulaszewski S (1997) The Saccharomyces cerevisiae ACR3 gene encodes a putative membrane protein involved in arsenite transport. J Biol Chem 272:30061-30066
76. Wysocki R, Chery CC, Wawrzycka D, Van Hulle M, Cornelis R, Thevelein JM, Tamas MJ (2001) The glycerol channel Fps1p mediates the uptake of arsenite and antimonite in Saccharomyces cerevisiae. Mol Microbiol 40:1391-1401
77. Yamamoto N, Sobue K, FujitaM, Katsuya H, Asai K (2002) Differential regulation of aquaporin-5 and -9 expression in astrocytes by protein kinase A. Brain Res Mol Brain Res 104:96-102
78. Yang HC, Cheng J, Finan TM, Rosen BP, Bhattacharjee H (2005) Novel pathway for arsenic detoxification in the legume symbiont Sinorhizobium meliloti. J Bacteriol 187:6991-6997
79. Zaman GJ, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Paulusma C, Oude Elferink RP, Baas F, Borst P (1995) Role of glutathione in the export of compounds from cells by the multidrugresistance- associated protein. Proc Natl Acad Sci USA 92:7690-7694
80. Zardoya R (2005) Phylogeny and evolution of the major intrinsic protein family. Biol Cell 97: 397-414
81. Zhou Y, Messier N, OuelletteM, Rosen BP, Mukhopadhyay R (2004) Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam. J Biol Chem 279:37445-37451
82. Zhou GB, Zhang J,Wang ZY, Chen SJ, Chen Z (2007) Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci 362:959-971